Pharming Group (OTCMKTS:PHGUF – Get Free Report) is anticipated to release its results before the market opens on Thursday, March 12th. Analysts expect Pharming Group to post earnings of $0.0015 per share and revenue of $89.7220 million for the quarter.
Pharming Group Stock Up 16.4%
OTCMKTS:PHGUF opened at $1.70 on Thursday. The business’s fifty day moving average price is $1.78 and its 200 day moving average price is $1.60. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.16 and a quick ratio of 2.39. Pharming Group has a 1-year low of $0.79 and a 1-year high of $2.17.
About Pharming Group
Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.
Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.
Read More
- Five stocks we like better than Pharming Group
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
